
Supplementary Figures

Long-Term Fostamatinib Treatment of Adults with Immune Thrombocytopenia (ITP) during the Phase 3 Clinical Trial Program. Bussel JB, Arnold DM, Boxer MA, Cooper N, Mayer J, Zayed H, Tong S, Duliege A. American Journal of Hematology. February 2019.

Figure S1. Kaplan-Meier estimate of the median duration of (a) first overall response including stable response and (b) first stable response.






Figure S2. Duration of response in stable responders. Arrow at the end of each lane indicates continuation of response and/or treatment. Note: End of response defined as two platelet counts <50,000/μL at least 4 weeks apart (or use of rescue therapy).




Figure S3. Median platelet levels over time in stable responders. Shaded area indicates timepoints with less than 10 patients contributing data.

